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Background and Purpose To yield large amounts of DNA for many genotype
analyses and to provide a renewable source of DNA, the Type 1 Diabetes Genetics
Consortium (T1DGC) harvested DNA and peripheral blood mononuclear cells
(PBMCs) from individuals with type 1 diabetes and their family members in several
regions of the world.
Methods DNA repositories were established in Asia-Pacific, Europe, North
America, and the United Kingdom. To address region-specific needs, different
methods and sample processing techniques were used among the laboratories to
extract and to quantify DNA and to establish Epstein-Barr virus transformed cell
lines.
Results More than 98% of the samples of PBMCs were successfully transformed.
Approximately 20–25mg of DNA were extracted per mL of whole blood. Extraction
of DNA from the cell pack ranged from 92 to 165mg per cell pack. In addition, the
extracted DNA from whole blood or transformed cells was successfully utilized in
each regional human leukocyte antigen genotyping laboratory and by several
additional laboratories performing consortium-wide genotyping projects.
Limitations Although the isolation of PBMCs was consistent among sites, the
measurement of DNA was difficult to harmonize.
Conclusions DNA repositories can be established in different regions of the world
and produce similar amounts of high-quality DNA for a variety of high-throughput
genotyping techniques. Furthermore, even with the distances and time necessary
for transportation, highly efficient transformation of PBMCs is possible. For future
studies/trials involving several laboratories in different locations, the T1DGC
experience includes examples of protocols that may be applicable. In summary,
T1DGC has developed protocols that would be of interest to any scientific
organization attempting to overcome the logistical problems associated with
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Abbreviations
cDNA complementary DNA
CIDR Center for Inherited Disease
Research
CSA cyclosporine
CV coefficient of variation
DMSO dimethylsulfoxide
dsDNA double stranded DNA
EBV Epstein-Barr virus
EDTA ethylenediaminetetraacetic acid
FBS fetal bovine serum
HBSS Hank’s buffered salt solution
HLA human leukocyte antigen
LCL lymphoblastoid cell line
MHC major histocompatibility complex
MIEs Mendelian inheritance errors
OD optical density
OPAs oligonucleotide pool assays
PBMC peripheral blood mononuclear cells
PBS phosphate-buffered saline
PCR polymerase chain reaction
PHA phytohemagglutinin
RBC red blood cell
RT room temperature
SDS sodium dodecyl sulfate
SE saline EDTA
SNP single nucleotide polymorphism
T1DGC Type 1 Diabetes Genetics
Consortium
TE Tris EDTA
USDA United States Department of
Agriculture
Introduction
Type 1 diabetes is a multi-factorial autoimmune
disease in which the insulin producing b-cells are
selectively destroyed [1]. The etiology of type 1
diabetes is only partially characterized; however, it
is generally accepted that a certain genetic predis-
position as well as environmental impacts [2]
increase the risk to develop the disease.
Furthermore, it is recognized that type 1 diabetes
is strongly clustered in families [3]. The Type 1
Diabetes Genetics Consortium (T1DGC) brought
together several groups of investigators worldwide
who shared the common goal of identifying genes
related to the etiologies of type 1 diabetes. With the
advent of high-throughput instrumentation to
process the DNA for its genetic information, more
research groups propose utilizing the DNA from
clinical studies and trials. A study involving large
numbers of subjects and laboratories needs to
harmonize the methods used to process and dis-
tribute the DNA to genotyping facilities.
From its inception, the T1DGC developed a
worldwide strategy with goals to collect whole
blood and to develop transformed cell lines from
peripheral blood mononuclear cells (PBMCs) for
current or later extraction of the DNA. The T1DGC
repositories extracted DNA and provided the sam-
ples to laboratories for human leukocyte antigen
(HLA) typing and genotyping. Furthermore, the
need for a rapid processing of the samples man-
dated establishment of repositories in several dif-
ferent locations: Asia-Pacific, Europe, North
America, and the United Kingdom.
Reliable measurement of DNA concentration is
important for many applications in molecular
biology. Common techniques that use DNA, such
as polymerase chain reaction (PCR), sequencing,
complementary DNA (cDNA) synthesis, and clon-
ing, all benefit from an accurately defined template
concentration. The most common reasons for
failure are low quantity and poor quality of the
DNA. The processes and protocols underlying
efforts of the T1DGC to provide adequate amounts
of high-quality DNA are described in this article.
Methods
Repositories
To address the needs of the clinical centers
throughout the world, repositories were established
in Asia-Pacific (Australian Red Cross Blood Service,
Melbourne, Australia), Europe (Ulm University,
Ulm, Germany), North America (Fred Hutchinson
Cancer Research Center, Seattle, WA, USA), and the
United Kingdom (Cambridge University,
Cambridge, UK).
Participants
Worldwide recruitment of the population is
described by Rich et al. [4] and Hilner et al. [5].
The fundamental need to recruit participants from
several geographic areas informed the decisions to
establish network-specific repositories, thereby
allowing efficient shipping of whole blood samples.
Within each region, procurement and processing of
samples from probands and their relatives were
identical. To minimize any differences in the
collection and processing of samples, all blood
collection tubes and fetal bovine serum (FBS) were
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Invitrogen, Inc., respectively) as described by
Hilner et al. [5]. A central source of the United
States Department of Agriculture (USDA) approved
FBS also was required to enable subsequent transfer
of the samples to a central repository in the United
States.
Isolation and transformation of PBMCs
PBMCs were isolated from whole blood by standard
ficoll–hypaque density gradient centrifugation.
Briefly, approximately 10mL of heparinized,
plasma-reduced blood was diluted with Hank’s
buffered salt solution (HBSS; 1:2 dilution). Then,
15mL of ficoll was covered with a layer of diluted
blood (30mL). After 30min of centrifugation
(2000rpm, room temperature (RT), without
break), the PBMCs could be easily collected. After
two washing steps and cell counting, the PBMCs
were prepared for transformation with Epstein-Barr
virus (EBV) added directly after isolation of the
PBMCs (Asia-Pacific and European DNA
Repositories); or the isolated PBMCs were frozen
and stored in a liquid nitrogen freezer for future
batch transformation (North American and United
Kingdom DNA Repositories). PBMCs were frozen in
FBS containing 10% dimethylsulfoxide (DMSO).
The protocols for transformation of cells were quite
similar whether the PBMCs were transformed after
isolation or after storage in liquid nitrogen (details
are provided below).
For transformation of previously frozen PBMCs,
the cells were thawed and washed in 10mL of
prewarmed HBSS to remove all traces of the cryo-
protectant in the freezing medium. Following cen-
trifugation at  300 g for 5min, the supernatant
was discarded; the pellet was then resuspended in
1mL of complete medium (RPMI 1640, 10–20%
heat inactivated FBS, 1% penicillin–streptomycin,
and 0.5% normocin or 0.1% gentamicin), and
transferred to a 25cm
2 flask containing 1.0–
2.0mL of EBV supernatant and 1.0mg of cyclospor-
ine (CSA) per mL. Approximately 6–7 10
6cells
were used for the transformation of both thawed
and freshly isolated PBMCs.
Freshly isolated PBMCs were suspended in 14mL
of complete medium (RPMI 1640 with Glutamax,
10% heat inactivated FBS, 1% penicillin–strepto-
mycin, and 0.5% normocin) in a 15mL of Falcon
tube, centrifuged at  350 g for 10min, and the
supernatant was discarded. The cells were then re-
suspended in 2.5mL of EBV supernatant and
2.5mL of complete medium, mixed carefully,
incubated for at least 3h (37 C; 6% CO2), and
transferred to a 25cm
2 tissue culture flask. In the
European, North American, and United Kingdom
Repositories, CSA (at a final concentration of 1mg/
mL) was used to suppress growth of T-lymphocytes.
The empty 15mL Falcon tube was rinsed with 5mL
of CSA containing medium before transferring the
CSA medium to the cells in the flask; and then the
10mL flask was placed in the incubator.
Alternatively, in Asia-Pacific, cells were re-sus-
pended in 4.0mL of complete medium supple-
mented with 5mg/mL of phytohemagglutinin-M
(PHA-M) instead of CSA and then transferred to a
25cm
2 tissue culture flask. EBV supernatant (1mL)
was added to the flask, mixed carefully, and then
the flask was placed in a humidified incubator
(37 C; 5% CO2).
The flasks were kept in a humidified incubator at
37 C and 5–6% CO2 throughout the culture period.
They may be left undisturbed for the first 21 days,
or may be subjected to additional procedures and/
or observations during this time. In the latter case,
on day 5, 0.3mL of PHA solution (100mg/mL) may
be added to the flask to augment the suppression of
T-lymphocytes. If the cultures were periodically
examined during the first 3 weeks of incubation,
they were first checked at day 5–7 by inverted phase
microscopy for bright refractile clumps of cells
(post-setup check). If there were a significant
number of clumps present, 1–3mL of complete
medium (including 5mL of CSA per mL) was added
to the flask, depending on the number of clumps,
and the flask was returned to the incubator. If there
were very few clumps of cells visible, no medium
was added, and the flask was returned to the
incubator to allow further growth before repeating
the post-setup check.
After 28–35 days of incubation, the cultures were
checked for sufficient cell numbers and split into
two portions, for freezing (one or more stock
aliquots) or for DNA extraction. The remaining
cells (1–20mL, depending on final culture volume)
were returned to a 25- or 75-cm
2 flask for expansion
to produce a sufficient number of cells for DNA
extraction or freezing.
Extraction of DNA
For whole blood samples, each laboratory first lysed
red blood cells (RBCs) from a blood sample with
reduced volume following removal of plasma. The
remaining white blood cells were treated in a
manner identical to that used on the cultured
PBMCs to isolate DNA. Three laboratories (Asia-
Pacific, Europe, and North America) used slight
variations of the ‘salting out’ method [6] and one
laboratory (United Kingdom) employed ‘chloro-
form’ extraction [7]. Briefly, as an example of the
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European DNA Repository is described.
After freezing and fast thawing of the cell
pack samples, the samples were diluted with
cold phosphate buffered saline (PBS). After the
addition of 3 volumes of ice-cold RBC lysis
buffer (155mM NH4Cl, 20mM KHCO3, 0.1mM
Na2EDTA; pH 7.4), the RBCs are lysed after 15min
of incubation on ice followed by centrifugation
(3000rpm, 10min, þ4 C) and decanting. After an
additional step of washing with RBC lysis buffer,
the white cell pellet was then re-suspended in 5mL
of saline EDTA (SE) buffer (75mM NaCl, 25mM
Na2EDTA; pH 8), 250mL sodium dodecyl sulfate
(SDS) (20%), and 5mL of RNAse and incubated at
37 C for 15–30min. After addition of 25mLo f
proteinase K (20mg/mL), the suspension was incu-
bated overnight at 37 C and 130rpm.
Next day, 5mL of SE buffer is added, followed by
2–3s of vortexing and at least 30min of incubation
at 55 C. After cooling to RT, 3mL of saturated 6M
NaCl solution was added to the cell lysate, followed
by immediate vortexing for exactly 25s. To keep
the SDS in the solution, the samples were then
centrifuged at 22 C (3500rpm, 10min).
Following centrifugation, the supernatants were
transferredtoa50-mLtubeandonevolumeof100%
isopropanol was added. To precipitate the DNA, the
samples were inverted gently 25 times. After an
overnight incubation at  80 C, the samples
were thawed at RT and centrifuged at 3500rpm for
10min at RT. The supernatants were decanted and
the DNA was re-suspended in 5mL of 70% ethanol
and again centrifuged (3500rpm, 10min, RT).
The supernatants were decanted and the DNA was
air dried for 1.5–2h at RT. The DNA was hydrated by
adding Tris EDTA (TE) solution (TEKNOVA, # T022;
volumeisdependentofthestrandsize).Togetbetter
resultsoftheDNAyieldandconcentration,theDNA
solution was incubated for at least 1h, at 55 Ct o
ensure complete hydration.
As mentioned above, in the United Kingdom
Network, DNA was extracted from blood with an
in-house extraction protocol using chloroform.
Initially, the red cells were lysed by washing twice
with lysis buffer (320mM sucrose, 1% Triton-X-
100, 5mM MgCl2, and 1mM Tris-HCl; pH 7.4),
followed by centrifugation (2500rpm, 15min) after
each addition of the buffer. The remaining white
cell pellet was digested overnight at 37 C with 4mL
of buffer (5.25M GuHCl, 463mM NH4Ac, 1.25% Na
sarcosyl) and 50mL of proteinase K (10mg/mL).
After cooling to RT, the extraction mix was trans-
ferred to 2mL of chloroform and vortexed until a
white emulsion formed. The tube was left to stand
for 1min before being centrifuged (2500rpm,
3min). The upper clear aqueous layer was removed
and transferred to 10mL of absolute ethanol. This
tube was then incubated at  20 C for at least 1h,
preferably overnight. Following incubation, the
tube was placed in a rotator for 5min at 40rpm to
precipitate the DNA. The DNA was pelleted
(3000rpm for 15min), and the ethanol was dis-
carded. The pellet was washed with 2mL of 70%
ethanol followed by centrifugation (3000rpm for
5min). The ethanol was discarded and the pellet
was left to air dry before being re-suspended in TE
buffer (10mM Tris, 0.1mM EDTA).
Measurement of DNA concentration
Absorbance
The most commonly used technique for measuring
nucleic acid concentration, absorbance at 260nm
(A260), utilizes an average extinction coefficient for
double-stranded (ds) DNA (1A260¼50mg/mL) to
determine the nucleic acid concentration from
the absorbance of the nucleic acid preparation.
Absorbance at 280nm (A280) permits estimation of
protein concentration in the sample. The optimal
density260/280 (OD260/280) ratio, reflecting the DNA
and protein concentrations, should fall between 1.6
and 2.0 to confirm that the preparation is free from
contamination with protein or RNA. For accurate
results, the A260 should be in the range 0.05–0.10,
which for a 1.0-mL assay, requires large amounts
(2.5–5.0mg) of dsDNA. For diluted nucleic acid
samples, the solution being measured should be
free of components that would add significantly to
the absorbance at 260nm. Limitations of the assay
include: the large contribution of nucleotides;
single-stranded nucleic acids and proteins to the
signal; the interference caused by additional con-
taminants; and the inability to distinguish between
DNA and RNA.
Fluorescence
Due to these limitations, alternate techniques have
been sought to provide more sensitivity and less
variation to the background absorbance. One such
alternative for quantitation of DNA is fluorescence.
PicoGreen dsDNA quantitation reagent employs a
‘CytoFluor Fluorescence Reader’, an eight-point
standard curve (0.11–14ng/mL), and three positive
assay controls (5, 10, and 15ng/mL). Samples are
assayed in triplicate; standards and controls in
duplicate with a coefficient of variation (CV)
calculated for each set of readings. Samples and
controls are excited at 480nm with the fluores-
cence emission intensity measured at 520nm.
Fluorescence emission intensity plotted versus
DNA concentration for the eight-point standard
curve allows for the sample concentrations to be
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readings from the standard curve.
DNA concentration of stock solutions
Stock DNA samples were normalized, according to
absorbance- or PicoGreen-determined concentra-
tions, to either 500 or 250ng/mL or left at the
determined concentration if measured to be lower
than 250ng/mL. To confirm the measured concen-
tration by comparison with the control DNA
sample, 2mL of the normalized stock DNA sample
was diluted to 100ng/mL and run out on 0.75%
agarose gel alongside a -Hind III ladder and a
control DNA sample (Lambda-DNA;  cl857 Sam 7;
Roche) also at 100ng/mL.
Results
Transformation of PBMCs
The different repositories utilized standardized,
though slightly different, protocols to transform
PBMCs to B-cell lines. Despite differences in relative
geographic areas, climatic extremes, and sample
transportation challenges, the overall transforma-
tion success rate across all the four networks was
high (98.4%) with no significant difference in the
success rate of the freshly transformed PBMCs
versus frozen, re-suspended PBMCs (Table 1).
The lower transformation rate observed in the
United Kingdom (93.9%) arose from contamina-
tion of 21 samples in the final batch. This was due
to use of a contaminated batch of PBS buffer
purchased as sterile from Inverclyde Biologicals,
which later turned out to be nonsterile due to a
breach in the sterilization procedure at the factory.
This buffer was used to dilute the working stock of
cyclosporine A that was added to the cells in the
first few days of culture, thereby introducing bac-
teria to the cultures. It took several weeks to
identify the source of the infection by which time
a large number of cultures had become contami-
nated. Prior to the inclusion of these failures in the
study database, the transformation rate in the
United Kingdom was comparable to the other
network repositories (i.e., 97.2%).
Parameters that might have affected the quality
of the blood sample and overall transformation
success rate were recorded and tracked for each
sample shipment, from recruitment center to DNA
repository. These included: transportation time
from blood sample collection to receipt at the
laboratories; storage conditions of blood samples
during transit; quality of blood samples on arrival
at the laboratory (e.g., whether blood samples were
hemolyzed or clotted or blood tubes were cracked
or broken en route); and low volume samples. The
T1DGC protocol dictated that the cell line and cell
pack samples be shipped on the day of collection
for receipt at the DNA Repository within 24h
(optimally). All clinics used courier companies for
shipping samples, with the exception of those
within the United Kingdom Network where the
postal service was used. Deviations from the proto-
col occurred when clinics did not ship on the day of
collection, and/or delays in shipping were encoun-
tered by courier companies.
Of the 12,745 samples shipped from clinical sites
to the T1DGC DNA Repositories, 6384 (50.1%) were
received within 24h from the time of blood collec-
tion (Table 2). Of these, 98.5% were successfully
transformed and 1.5% failed. An additional 4577
samples (35.9%) were received by the repositories
between  24 and <48h, with 98.1% of these
samples successfully transformed and 1.9% failing.
The transformation rate for samples in transit
between  48 and <72h (n¼636; 5.0%) was
98.4%, and it was 99.3% for samples in transit
between  72 and <96 (n¼281; 2.2%). Even for
samples that arrived at the repositories more than 4
days after collection (n¼867; 6.8%), the transfor-
mation rate was 97.5%. There was no correlation
between sample transit time and successful trans-
formation, either overall (r¼0.02, p¼0.07) or
within the network.
Quantity of DNA extracted from whole blood
cell packs
Isolation of DNA from the residual cell pack of a
5mL of whole blood sample (collected in an EDTA
vacutainer) was performed using a modified salting
out procedure or chloroform extraction,
Table 1 PBMC transformation rates, by network and overall, T1DGC, July 4, 2009
Network Total samples Samples transformed Failed In process Success (%)
Asia-Pacific 2208 2050 42 116 98.0
European 4848 4785 61 2 98.7
North American 6422 6191 72 159 98.9
United Kingdom 676 635 41 0 93.9
Overall 14,154 13,661 216 277 98.4
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extracted from 14,022 EDTA cell pack samples,
with an average yield of 144mg (range: 92–165mg)
(Table 3). Differences in yields across the laborato-
ries reflected differences in the volumes of samples
received and protocols used in the laboratories.
Quantity of DNA extracted from lymphoblastoid
cell lines
Isolation of DNA from lymphoblastoid cell lines
(LCL) in the four network laboratories using two
basic extraction methods [6,7] consistently yielded
robust quantities of DNA of extremely high quality
(Table 4). As of July 4, 2009, 13,614 LCL samples
had been extracted in the four laboratories, with an
average yield of 365mg (range: 238–709mg) DNA per
B-LCL.
Quality of DNA extracted from whole blood cell
packs and LCL
The quality of DNA was assessed by agarose gel
electrophoresis. The analysis of each DNA sample
extraction by agarose gel electrophoresis, including
a molecular weight standard (Invitrogen), showed
Table 2 Summary of sample transit time and cell line transformation outcome, by network and overall, T1DGC, July 4, 2009
Asia-Pacific European North American United Kingdom Overall
N (%) N (%) N (%) N (%) N (%)
Transit time (h) Transformation
<24 Success 829 (96.9) 2170 (98.8) 3107 (98.8) 184 (98.4) 6290 (98.5)
Failure 27 (3.2) 26 (1.2) 38 (1.2) 3 (1.6) 94 (1.5)
Total (%N) received 856 (62.6) 2196 (44.9) 3145 (54.4) 187 (26.5) 6384 (50.1)
 24 and <48 Success 358 (97.6) 2101 (98.4) 1772 (98.9) 260 (91.9) 4491 (98.1)
Failure 9 (2.5) 35 (1.6) 19 (1.1) 23 (8.1) 86 (1.9)
Total (%N) received 367 (26.9) 2136 (43.7) 1791 (31.0) 283 (40.1) 4577 (35.9)
 48 and <72 Success 52 (100.0) 205 (99.5) 318 (99.4) 51 (87.9) 626 (98.4)
Failure – 1 (0.5) 2 (0.6) 7 (12.1) 10 (1.6)
Total (%N) received 52 (3.8) 206 (4.2) 320 (5.5) 58 (8.2) 636 (5.0)
 72 and <96 Success 9 (100.0) 61 (100.0) 109 (100.0) 100 (98.0) 279 (99.3)
Failure – – – 2 (2.0) 2 (0.7)
Total (%N) received 9 (0.7) 61 (1.3) 109 (1.9) 102 (14.5) 281 (2.2)
 96 Success 78 (94.0) 290 (98.6) 408 (98.3) 69 (92.0) 845 (97.5)
Failure 5 (6.0) 4 (1.4) 7 (1.7) 6 (8.0) 22 (2.5)
Total (%N) received 83 (6.1) 294 (6.0) 415 (7.2) 75 (10.6) 867 (6.8)
Overall total received 1367 (100.0) 4893 (100.0) 5780 (100.0) 705 (100.0) 12,745 (100.0)
Table 3 Summary of DNA extraction yield from EDTA cell packs, by network and overall, T1DGC, July 4, 2009
Network Total samples (N) DNA extraction method Average yield per sample (mg)
a
Asia-Pacific 2131 Salting out 102.9
European 4836 Salting out 143.0
North American 6393 Salting out 164.9
United Kingdom 662 Chloroform 91.7
Overall 14,022 144.5
aDefined by OD at 260/280nm.
Table 4 Summary of DNA extraction yield from LCL, by network and overall, T1DGC, July 4, 2009
Network Total samples (N) Culture vessel surface area (cm
2) Average yield per sample (mg)
a
Asia-Pacific 2077 75 709.4
European 4793 75 390.4
North American 6108 25 237.7
United Kingdom 636 75 266.5
Overall 13,614 364.8
aDefined by OD at 260/280nm.
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samples. This is indicative of high molecular weight
DNA and absence of DNA degradation. Inclusion of
lambda DNA markers (Roche Molecular Systems) in
each gel provided additional quantity controls for
the test DNA samples and demonstrated compara-
ble sample-by-sample results to the DNA quantified
by OD measurement (Figure 1).
HLA genotyping
In general, the extracted DNA from whole blood
cell packs (primary sample source) or PBMCs was of
high quality and was successfully utilized in the
HLA genotyping method utilized in T1DGC [8].
Overall, only 50 (0.4%) of the 13,373 samples
genotyped were noted as failures and an additional
48 (0.4%) as contaminated (Table 5). Contamina-
tion could have occurred at either the DNA repos-
itory or at the HLA genotyping laboratory during
sample aliquoting. Mendelian inheritance errors
(MIEs) were found in 92 (2.7%) of the genotyped
families. To date, all but four of the MIEs were
resolved as follows: 32 (34.8%) were deemed as
genotyping errors at the HLA laboratories; 27
(29.3%) were sample mix-ups at the DNA reposito-
ries; and 29 (31.5%) were classified as probable
nonbiological relationships (e.g., half-siblings,
paternity issues). A total of 171 samples (1.3%)
were requested as replacement samples by the HLA
genotyping laboratories.
Additional genotyping projects
In addition, the T1DGC utilized several laborato-
ries, including the Center for Inherited Disease
Research (CIDR, Johns Hopkins University,
Baltimore, MD, USA), the Wellcome Trust Sanger
Institute (Cambridge, UK), and the Broad Institute
(Massachusetts Institute of Technology/Harvard
University, Cambridge, MA, USA) to complete the
genotyping of thousands of samples from T1DGC
as well as other existing collections from a variety
of populations. A general assessment of the overall
quality of the T1DGC DNA samples submitted as
well as potential sample labeling or aliquoting
errors can be obtained by examining sample fail-
ures, MIEs, sample switches, and gender discrepan-
cies for each of the genotyping projects (Table 6).
Sample labeling errors could have occurred at the
clinic collection site during sample collection or at
the DNA repository during sample preparation or
aliquoting. Aliquoting errors also could have
occurred at either the DNA repository or the
genotyping facility (if samples were re-aliquoted
prior to or during the production phase of the
project).
Across all the four T1DGC repositories, DNA was
extracted from both LCLs and whole blood cell
packs. The isolated DNA was then sent to a variety
of genotyping laboratories for analysis by various
methods, using a number of different platforms.
The genotyping results obtained from the
various laboratories, using the isolated DNA,
were all excellent, regardless of the platform used
[9–11].
Genome-wide 6K single nucleotide polymorphism
analysis (CIDR)
The T1DGC repositories submitted 11,523 samples
with 10mg of genomic DNA (100mL at 100ng/mL)
to CIDR for 6K genome-wide single nucleotide
polymorphism (SNP) analysis. Samples were ali-
quoted into 96-well plates supplied by CIDR, with
two quality control samples and two empty wells
(for control samples) per plate, for genotyping
using the Illumina Human Linkage-12
Genotyping Beadchip consisting of 6090 SNPs on
the Illumina platform. Of the production samples
submitted, only 111 (1.0%) were noted as failures.
Sixty-eight samples (0.6%) resulted in MIEs;
11 (0.1%) indicated gender discrepancies (as com-
pared with the phenotypic data from data collec-
tion forms); and 68 (0.6%) indicated sample
switches. A total of 197 replacement samples
(1.7%) were requested.
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Figure 1 DNA sample quality control. To confirm quality and
quantity of the isolated DNA, agarose gel electrophoresis of
each DNA sample was performed. By adding the smart ladder,
the measured concentration of 250ng/mL, which was obtained
performing OD measurement, could be visually confirmed.
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(The Wellcome Trust Sanger Institute)
The T1DGC repositories submitted 4592 samples
with 10mg of genomic DNA (100mL at 100ng/mL)
to Sanger for genotyping analysis on two 1536 SNP
oligonucleotide pool assays (OPAs) and 63 micro-
satellites in the major histocompatibility complex
(MHC) region. Samples were aliquoted into 96-well
plates, with two quality control samples and one
empty well (for control samples) per plate, for
genotyping on the Illumina platform; microsatel-
lites were genotyped at deCODE (Iceland). Of the
production samples submitted, only 38 (0.8%) were
noted as failures on OPA1 and 32 (0.7%) on OPA2.
Sample failures were slightly higher for microsatel-
lites (1.8%). Forty samples (0.9%) resulted in MIEs;
two (0.0%) indicated gender discrepancies; and 18
(0.4%) indicated sample switches. A total of 117
replacement samples (2.5%) were requested.
Rapid response (The Broad Institute)
The T1DGC repositories submitted 4595 samples
with 5mg of genomic DNA (50mL at 100ng/mL) to
the Broad Institute for 384 SNP analysis on two
platforms (Illumina and Sequenom). Samples were
aliquoted into 96-well plates, with two quality
control samples and one empty well (for control
samples) per plate. Of the production samples
submitted, there were 126 (2.7%) failures on the
Illumina platform and 181 (3.9%) on the
Table 6 Summary of sample outcomes for genotyping projects, by network and overall, T1DGC, July 4, 2009
Asia-Pacific
N (%)
European
N (%)
North American
N (%)
United Kingdom
N (%)
Total
N (%)
6K Genome scan (CIDR)
N 1338 4741 4813 631 11,523
MIEs 7 (0.5) 32 (0.7) 27 (0.6) 2 (0.3) 68 (0.6)
Failures 8 (0.6) 28 (0.6) 65 (1.4) 10 (1.6) 111 (1.0)
Gender discrepancies 2 (0.1) 7 (0.1) 2 (0.0) 0 (0.0) 11 (0.1)
Sample switches 16 (1.2) 12 (0.3) 40 (0.8) 0 (0.0) 68 (0.6)
Replacements 9 (0.7) 66 (1.4) 109 (2.3) 13 (2.1) 197 (1.7)
MHC fine mapping (The Wellcome Trust Sanger Institute)
N 782 1953 1373 484 4592
MIEs 4 (0.5) 13 (0.7) 17 (1.2) 6 (1.2) 40 (0.9)
Failures – OPA1 5 (0.6) 15 (0.8) 14 (1.0) 4 (0.8) 38 (0.8)
Failures – OPA2 6 (0.8) 3 (0.2) 9 (0.7) 14 (2.9) 32 (0.7)
Failures – microsatellites 13 (1.6) 38 (1.9) 20 (1.5) 12 (2.5) 83 (1.8)
Gender discrepancies 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.4) 2 (0.0)
Sample switches 4 (0.5) 6 (0.3) 6 (0.4) 2 (0.4) 18 (0.4)
Replacements 18 (2.3) 29 (1.5) 39 (2.8) 31 (6.4) 117 (2.5)
Rapid response (The Broad Institute)
N 782 1953 1376 484 4595
MIEs 5 (0.6) 13 (0.7) 9 (0.7) 8 (1.7) 35 (0.8)
Failures – llumina 19 (2.4) 12 (0.6) 53 (3.9) 42 (8.7) 126 (2.7)
Failures – Sequenom 26 (3.3) 55 (2.8) 75 (5.5) 25 (5.2) 181 (3.9)
Gender discrepancies 0 (0.0) 0 (0.0) 1 (0.1) 2 (0.4) 3 (0.1)
Sample switches 2 (0.3) 6 (0.3) 8 (0.6) 0 (0.0) 16 (0.3)
Table 5 Summary of sample outcomes for classical HLA genotyping, by network and overall, T1DGC, July 4, 2009
Asia-Pacific
N (%)
European
N (%)
North
American
(Class I) N (%)
North
American
(Class II) N (%)
United
Kingdom
N (%)
Total
N (%)
N participants (families) 2029 (579) 4854 (1287) 5822 (1385) 5822 (1385) 668 (169) 13,373 (3420)
MIEs
a 26 (4.5) 23 (1.8) 32 (2.3) 33 (2.4) 3 (1.8) 92 (2.7)
Failures 3 (0.1) 2 (0.0) 36 (0.6) 36 (0.6) 9 (1.3) 50 (0.4)
Contaminated samples 7 (0.3) 5 (0.1) 13 (0.2) 13 (0.2) 23 (3.4) 48 (0.4)
Replacements 24 (1.2) 22 (0.5) 83 (1.4) 83 (1.4) 42 (6.3) 171 (1.3)
aN (%) MIEs is based on number of families.
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resulted in MIEs; three (0.1%) indicated gender
discrepancies; and 16 (0.3%) indicated sample
switches.
Discussion
The T1DGC was established to unite several groups
of investigators worldwide who shared the
common goal of identifying genes relating to the
etiologies of type 1 diabetes mellitus. The recruit-
ment protocols of the T1DGC allowed many more
probands, relatives, and families to be recruited
than was previously possible in country- or region-
wide efforts. Establishing regional DNA repositories
was a logical response to worldwide recruitment.
Implementation of the repositories allowed these
central processes to be located near the clinical
centers, thus minimizing time in shipment. Other
advantages subsumed dissemination of technical
expertise, including benefits of scientific coopera-
tion among several regions, distribution of work-
load for genotyping projects among several
laboratories, rapid and efficient distribution of
samples to investigators, and utilization of vali-
dated quality control procedures throughout the
Consortium.
To yield transformed cells, whole blood samples
were collected and sent the same day by overnight
courier (or equivalent) to the laboratory for the
Asia-Pacific, European, and North American
Repositories. The Asia-Pacific and European
Repositories processed all samples to the point of
initiating the transformation cultures on the day
they were received, which often necessitated a long
working day to complete the processing. The North
American and United Kingdom Repositories
processed the samples to the point of PBMC
isolation only, with the PBMCs being frozen for
later transformation. This allowed the initial pro-
cessing of the blood specimens to be divided into
two phases, reducing the overall time required for
processing on the day of receipt as well as permit-
ting the ‘batch’ transformation of frozen–thawed
PBMCs. This latter strategy had the advantage of
batch-processing time savings and the synchroni-
zation of transforming cultures.
Either modality worked satisfactorily in the
T1DGC. Thus, the long distances for shipping in
Asia-Pacific did not reduce the yield of the trans-
formed cells. Among the four laboratories, the
different processes outlined above generally pro-
duced quite similar results (i.e., the success in
transformation was very high and nearly identical
among the repositories). The explanations for
transformation failures (i.e., collection vagaries,
transportation issues, and intra-laboratory prob-
lems) were similar among the regions. Although we
expected Asia-Pacific to encounter the greatest
challenges due to the long distances required for
shipping, their transformation rates were very good
and similar to those achieved by others. These
results support the resilience of cell line samples as
well as the ability of the repositories to achieve
transformation when delivery to the laboratory was
delayed.
The variation in cell line DNA yields among the
laboratories may have been in part related to the
different DNA extraction protocols used. However,
it is also possible that the primary source of
variation was due to the different culture vessels
with different volumes for culture employed for
growing the cell lines (i.e., flasks with 25cm
2 vs
75cm
2 surface area), and thus the number of
PBMCs per flask subjected to DNA extraction.
The provision of large amounts of DNA is the
central goal of many different studies. We estab-
lished a robust and workable model that other large
multi-center, multi-regional epidemiologic studies,
or clinical trials can follow. We measured the
amounts of DNA, aliquoted DNA for additional
testing successfully completed in many facilities,
and checked for errors at many steps in the process.
In its final accomplishments, the T1DGC estab-
lished a centralized cell bank that will continue to
provide a reference for diabetes research. The
availability of well-characterized, viable lympho-
blastoid human cells, which can also be used for
functional studies along with pertinent data on the
specific patient group, is a renewable resource that
will permit state-of-the-art biomedical research.
T1DGC quality control programs guided each of
the laboratories and genotyping facilities and facil-
itated efficient completion of the protocols and
procedures. Overall, the results demonstrate success
at all levels of endeavor: from collection to ship-
ping to processing and finally to analyses and
reporting to the Coordinating Center. Furthermore,
the quality control checks for quality and consis-
tency of materials and assays allowed the T1DGC to
document the success of the enterprise: provision
of high-quality DNA for genotyping on many
different platforms for contrasting and intersecting
goals to elucidate the genetics of type 1 diabetes.
Finally, the careful documentation within the
T1DGC showed what parameters were important
for the success of the Consortium.
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